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Abstract
Purpose The hypothesis in this study was that anaemia prior
to surgery and perioperative red blood cell transfusion in-
creases the risk for recurrence and overall mortality in patients
with stages I–III colorectal cancer after abdominal resection
with curative intent.
Methods This is a Swedish single centre retrospective cohort
study. Data on 496 consecutive radical abdominal resections
stages I–III colorectal cancer performed at the Karolinska
University Hospital 2007–2010 were extracted from the
Swedish Colorectal Cancer Registry. Data were linked to local
laboratory and transfusion databases to identify preoperative
anaemia and perioperative transfusion. Disease recurrence
was validated by scrutiny of patient records. A total of 496
stages I–III colorectal cancer patients were included in the
analysis. Multivariate Cox regression analysis adjusted for
tumour and patient characteristics were performed to assess
risk for recurrence and overall mortality.
Results Anaemia prior to surgery was associated with in-
creased risk for overall mortality (HR 2.1, 95% CI 1.4–3.2).
There was no association between anaemia and risk for recur-
rence (HR 1.6, 95% CI 0.97–2.6). Transfusion was not asso-
ciated with increased risk of recurrence (HR 0.7, 95% CI 0.4–
1.3) or overall mortality (HR 1.04, 95% CI 0.7–1.6).
Conclusions Anaemia prior to colorectal cancer surgery was
associated with increased risk for overall mortality while a no
increased risk was seen for recurrence. Previous findings in-
dicating an association between blood transfusion and in-
creased risk for recurrence could not be confirmed.
Keywords Anaemia . Transfusion . Colorectal cancer .
Recurrence .Mortality . Survival
Introduction
Anaemia is common in colorectal cancer [1–3] (CRC), with a
reported prevalence ranging from 23 to 75 % [1–4].
Worldwide, CRC is the third most common cancer in men
and second most common in women [5]. Iron deficiency
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anaemia in CRC thus constitutes an important clinical prob-
lem with no clear guidelines for management. Anaemia in
CRC patients is mainly caused by bleeding from the tumour;
either occultly from a proximal colon tumour [2, 6], or with
visible faecal blood from distal colon tumours or rectal can-
cers [2, 7]. However, anaemia can also be caused by a system-
ic inflammatory response to the tumour [8].
Iron deficiency anaemia can be corrected by blood transfu-
sion or by the administration of iron medication prior to sur-
gery [9]. Perioperative blood transfusion is considered to be
associated with an increased risk for recurrence in CRC pa-
tients operated with curative intent [10]. This dose-dependent
negative effect was independent of stage or when, during the
perioperative period, the transfusion was administered [10].
The importance of anaemia in patients with CRC has only
been investigated in a few studies. Anaemia has been associ-
ated with more advanced stage [11] and higher mortality [11,
12]. In another study on patients with T3N0M0 and T4N0M0
colon cancer, impaired disease-free survival associated with
anaemia was only seen in the former group [13].
The hypothesis tested in this study was that preoperative
anaemia and perioperative red blood cell transfusion, in pa-
tients with localised CRC undergoing curative resection, in-
crease the risk for recurrence and overall mortality.
Materials and methods
Data sources
This is a single centre, retrospective cohort study, on re-
sections for CRC stages I–III performed at the Karolinska
University Hospital 2007–2010. Data on all consecutive
patients living in the region were retrieved from the
Swedish Colorectal Cancer Registry (SCRCR) [14, 15]
on 7 January 2014. Data were not retrieved on patients
referred from other regions since they are followed up
where they live. The SCRCR, including prospectively
collected data, contains information on the patient, neo-
adjuvant treatment, surgical procedure, tumour character-
istics, and short- and long-term follow-up. Information on
all red cell concentrate transfusions was obtained from the
local blood transfusion database [16], and on all preoper-
ative haemoglobin concentrations from the local laborato-
ry database. For patients with no available records in the
laboratory database (n = 21), data on preoperative
haemoglobin concentrations were obtained through re-
view of case records. Information on recurrence was val-
idated by scrutiny of patient records and entered into a
common database. Record linkage was performed using
the patient’s unique national registration number assigned
to all Swedish citizens upon birth or immigration [17].
After local processing, records from the SCRCR,
transfusion and laboratory databases were submitted to
the Swedish National Board of Health and Welfare for
further record linkage with data not used in this study
and anonymisation of the database.
Only resections judged as locally radical and curative
by the surgeon and radical by the pathologist (R0) were
included (leaving 546 patients). Patients previously oper-
ated for CRC (n = 12) or operated for metachronous
CRCs (n = 16) during the study period were excluded.
Patients dying during the initial 30 days after surgery or
within the same hospital stay if longer (n = 14) and pa-
tients with missing haemoglobin values (n = 8) were also
excluded leaving 496 patients for the final analysis: 282
colon cancers and 214 rectal cancers.
Main outcomes were recurrence and overall death.
Anaemia was defined according to the WHO classifi-
cation of anaemia for the adult population (age ≥ 15 years);
a haemoglobin less than 120 g/l in non-pregnant
women and a haemoglobin less than 130 g/l in men [18]
within 2 months before the date of surgery. Transfusion
was defined as having received at least one allogeneic
red blood cell transfusion within 1 day of surgery.
Analyses were also performed for patients receiving a
transfusion within 30 days of surgery. Operations were
classified and divided into three groups: colon resection,
low anterior resection and Hartmann’s procedure (for
rectal cancer) and a third group with abdomino-perineal
resection.
A local recurrence or metastases diagnosed by radiolo-
gy or histopathology and verified by viewing the patient
records was defined as a recurrence.
Statistical analysis
Categorical variables were described as frequency and
percentages. Age was described as median with interquar-
tile range (IQR).
Differences in the distribution of gender, tumour site,
ASA class, pT Stage and pN stage between patients with
and without anaemia were analysed using the chi-square
test. Multivariate adjusted analyses were performed using
the Cox Proportional Hazards model for calculation of
Hazard ratios. The multivariate analyses were adjusted
for parameters suspected of being associated both with
anaemia/transfusion and risk for recurrence and overall
mortality; gender, ASA class, pT Stage, pN Stage, type
of surgery and neo-adjuvant treatment, all as categorical
variables, and for age and blood loss as restricted cubic
splines with three degrees of freedom [19, 20]. This made
it possible to adjust for age and blood loss as functions of
continuous variables.
In the analysis of risk for recurrence, patients were
followed from the date of surgery until the date of first
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recurrence, death or end of follow-up (2014-01-07),
whichever came first. In the analysis of overall mortality,
patients were followed from the date of surgery until date
of death, or end of follow-up (2014-01-07), whichever
came first. Data are presented as hazard ratios (HR) with
95 % confidence intervals (CI). Relative risk is used in
the text as being equivalent to hazard ratio.
To assess the appropriateness of including both anaemia
and transfusion in the same regression model, co-linearity
between these variables was tested using the chi-square test.
This analysis revealed some evidence of moderately strong
co-linearity, and we therefore conducted separate analyses
and analyses with both variables in the same model.
Kaplan-Meyer curves showing risk for recurrence and
overall survival were compared with log-rank test to test for
significant differences between groups.
A p value <0.05 was considered statistically significant.
STATA/IC 11.2 was used for statistical analyses and figures.
Results
Patient characteristics according to grade of anaemia and
blood transfusion are given in Tables 1 and 2. Of the
anaemic patients, 150 (58 %) received a transfusion with-
in 24 h of surgery compared to 49 (21 %) of the non-
Table 1 Patient characteristics of 496 patients undergoing curative
abdominal resections for stage I–III colorectal cancer
Patient characteristics No anaemia Anaemia
Subjects, N (% of total) 239 (48.2) 257 (51.8)
Female, N (%) 115 (48.1) 119 (46.3)
Median age (year) at diagnosisa (IQR) 67 (61–74) 70 (62–79)
Number CRC, no. (%)
Colon 115 (48.1) 167 (65.0)
Rectum 124 (51.9) 90 (35.0)
ASA, N (%)
1 50 (20.9) 30 (11.7)
2 132 (55.2) 113 (44.0)
3 48 (20.1) 100 (38.9)
4 9 (3.8) 14 (5.4)
pT stage, N (%)
1 43 (18.0) 14 (5.4)
2 66 (27.6) 27 (10.5)
3 109 (45.6) 154 (59.9)
4 21 (8.8) 62 (24.1)
pN stage, N (%)
0 173 (72.4) 178 (69.3)
1 51 (21.3) 50 (19.5)
2 15 (6.3) 29 (11.3)
Type of surgery, N (%)
Colon resection 115 (48.1) 166 (64.6)
Low anterior resection + Hartmannb 83 (34.7) 50 (19.5)
Abdomino-perineal resectionc 41 (17.2) 41 (16.0)
Neo-adjuvant treatment, N (% )
(Chemo) radiotherapyb 99 (79.8) 73 (81.1)
Chemotherapy only 1 (0.4) 6 (2.3)
All percentages are given as percentage of number of patients within
group for no anaemia/anaemia unless stated otherwise
aMedian age patients with colon cancer 71 years, median age patients
with rectal cancer 65 years
b Only patients with rectal cancers
c Including one patient with colon cancer in the anaemic group
Table 2 Patient characteristics of 496 patients undergoing curative
abdominal resections for stage I–III colorectal cancer
Patient characteristics No transfusion Transfusion
Subjects, N (% of total) 297 (59.9) 199 (40.1)
Female, N (%) 136 (45.8) 98 (49.2)
Median age (year) at diagnosisa (IQR) 66 (61–73) 73 (63–80)
Number CRC, no. (%)
Colon 173 (58.2) 109 (54.8)
Rectum 124 (41.8) 90 (45.2)
ASA, N (%)
1 70 (23.6) 10 (5.0)
2 149 (50.2) 96 (48.2)
3 70 (23.6) 78 (39.2)
4 8 (2.7) 15 (7.5)
pT stage, N (%)
1 43 (14.5) 14 (7.0)
2 67 (22.6) 26 (13.1)
3 155 (52.2) 108 (54.3)
4 32 (10.8) 51 (25.6)
pN stage, N (%)
0 213 (71.7) 138 (69.3)
1 59 (19.9) 42 (21.1)
2 25 (8.4) 19 (9.5)
Type of surgery, N (%)
Colon resection 173 (58.2) 108 (54.3)
Low anterior resection + Hartmannb 82 (27.6) 51 (25.6)
Abdomino-perineal resectionc 42 (14.1) 40 (20.1)
Neo-adjuvant treatment, N (% )
(Chemo) radiotherapyb 97 (78.2) 75 (83.3)
Chemotherapy only 3 (1.0) 4 (2.0)
All percentages are given as percentage of number of patients within
group (not transfused/transfused within 24 h before or after surgery) un-
less stated otherwise
aMedian age patients with colon cancer 71 years, median age patients
with rectal cancer 65 years
b Only patients with rectal cancers
c Including one patient with colon cancer for the transfused patients
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anaemic patients. In total, 199 patients in the cohort re-
ceived a red cell blood transfusion within 24 h of their
resection. In addition, 46 patients received transfusion
more than 24 h before or after surgery within 30 days
before or after surgery.
Colon cancer, more advanced ASA class and pT Stage
were all significantly associated with anaemia (p < 0.001)
whereas gender (p = 0.69) and pN stage (p = 0.14) were not
significantly associated with anaemia.
The log-rank test analysis revealed that patients suffering
from anaemia prior to surgery had a significantly increased
risk for recurrence (p = 0.002) (Fig. 1), while the multivariate
model with anaemia as dependent variable was not significant
(HR 1.6, 95%CI 0.97–2.6). There was no association between
receiving blood transfusion within 24 h of surgery and risk for
recurrent disease (HR 0.7, 95% CI, 0.4–1.3) (Table 3, Fig. 2).
Multivariate Cox regression analysis was also conducted for
patients receiving a transfusion within 30 days of surgery (HR
0.7, 95% CI 0.4–1.2).
Anaemia prior to surgery was also associated with poorer
overall survival (HR 2.1, 95% CI 1.4–3.2) (Table 4, Fig. 3).
There was no association between blood transfusion and over-
all survival in the multivariate Cox regression analysis (HR
1.04, 95% CI 0.7–1.6) (Table 4) while the survival analysis
tested with log-rank test was significant (Fig. 4).
The analysis including both anaemia and transfusion as
independent variables in the same model revealed an associa-
tion between anaemia and risk for recurrence (HR 1.7, 95%CI
1.1–2.9) (Table 3), and death (HR 2.3, 95% CI 1.5–3.6)
(Table 4). There was no association between transfusion and
either of these outcomes (Table 3, Table 4).
Discussion
Preoperative anaemia, present in approximately 50 % of the
CRC patients in this study, was a strong predictor for impaired
survival. There was no significantly increased risk of cancer
recurrence in patients with preoperative anaemia. Blood trans-
fusion was neither associated with increased risk for recur-
rence, nor with overall mortality in the present study.
This is a single centre retrospective cohort study using pro-
spectively registered registry data. Consecutive patients un-
dergoing radical abdominal resection for stages I–III CRC at
the Karolinska University Hospital and living in the region
were included. The minimum follow-up time in the study
was 3 years. Karolinska University Hospital is one of the
largest centres in Sweden, taking advanced cases from the
Stockholm Region. Patients referred from other regions were
not included in the trial since they are followed up at their
nearest hospital.
For each patient, the lowest of all haemoglobin values reg-
istered within 2 months before the date of surgery was chosen
for classification of anaemia. This was to minimise the risk of
patients receiving preoperative ironmedication or blood trans-
fusion and being misclassified.
Data on blood transfusion was collected 2 months before
surgery until 1 month after surgery. Analyses were performed
Fig. 1 Proportion of patients,
operated for CRC stages I–III,
without recurrence divided in
patients with preoperative
anaemia and no anaemia. p value
represents log-rank test
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for patients receiving blood transfusions within 1 day before
or after surgery, since this time interval was considered the
most interesting period with respect to impaired immunolog-
ical response of the patient at the time of surgical trauma. One
hundred ninety-nine patients (81% of patients receiving blood
transfusion) did so within this time interval. It can be argued
that the immunological effect of blood transfusion in combi-
nation with surgical stress can be longer. Additional analyses
for the period 1 month before or after surgery were performed
regarding recurrent disease and survival.
The only available measure of co-morbidity was ASA
class. This factor was adjusted for in the multivariate
models since it was suspected to influence both survival
and the risk for anaemia.
Abdomino-perineal resection is known to be associat-
ed with a higher risk for recurrence [21], hence the
analyses were adjusted for surgical procedure.
Although, such an association could not be shown in
the current study. Analyses were also performed when
dividing colonic resections into acute and elective pro-
cedures [22]. This did not affect the outcome estimates,
and colon resections were thus analysed as one group.
The stage reported to the SCRCR is the stage derived
from examination of the pathology specimen. Since
Table 3 Multivariate Cox regression analysis for risk of recurrence of 496 patients undergoing curative abdominal resections for stages I–III colorectal
cancer
Preoperative anaemia Transfusion (± 1 day) Preoperative anaemia
and transfusion
Events/person-years Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI)
Anaemia
Yes 58/953.8 1.6 (0.97–2.6) ns 1.7 (1.1–2.9)*
No 32/1046.6 1.00 (ref) 1.00 (ref)
Transfusion
Red blood cell 35/792.5 0.7 (0.4–1.3) ns 0.6 (0.4–1.1) ns
No transfusion 55/1207.9 1.00 (ref) 1.00 (ref)
Sex
Female 39/983.8 0.8 (0.5–1.2) ns 0.8 (0.5–1.3) ns 0.8 (0.5–1.4) ns
Male 51/1016.6 1.00 (ref) 1.00 (ref) 1.00 (ref)
ASA grade
1 20/329.5 1.00 (ref) 1.00 (ref) 1.00 (ref)
2 43/1052.3 0.9 (0.5–1.6) ns 0.9 (0.5–1.8) ns 0.9 (0.5–1.8) ns
3 23/539.1 0.7 (0.3–1.5) ns 0.9 (0.4–1.8) ns 0.8 (0.4–1.8) ns
4 4/79.6 1.4 (0.4–4.6) ns 1.8 (0.5–6) ns 1.8 (0.5–6.1) ns
pT
1 2/264.7 1.00 (ref) 1.00 (ref) 1.00 (ref)
2 7/388.8 1.7 (0.3–8.3) ns 1.6 (0.3–8) ns 1.6 (0.3–7.9) ns
3 49/1054.7 4.9 (1.2–20.6)* 5.4 (1.3–22.6)* 4.7 (1.1–19.9)*
4 32/292.2 12.3 (2.8–53.8)** 15.9 (3.7–68.1)*** 12.3 (2.8–53.5)**
pN
0 48/1466.1 1.00 (ref) 1.00 (ref) 1.00 (ref)
1 17/420.4 1.3 (0.7–2.3) ns 1.3 (0.7–2.3) ns 1.3 (0.8–2.4) ns
2 25/113.9 4.7 (2.8–8)*** 4.8 (2.9–8.2)*** 5 (3–8.5)***
Type of surgery
Colon resection 38/1127.8 1.00 (ref) 1.00 (ref) 1.00 (ref)
Low anterior resection + Hartmann 31/556.1 2.1 (0.9–5) ns 1.9 (0.8–4.6) ns 2 (0.8–4.9) ns
Abdomino-perineal resection 21/316.4 2.3 (0.9–6.1) ns 2.2 (0.8–6.1) ns 2.1 (0.8–5.8) ns
Neo-adjuvant treatment
Yes 46/714.5 1.4 (0.6–3.1) ns 1.4 (0.6–3.1) ns 1.4 (0.6–3.2) ns
No 44/1285.9 1.00 (ref) 1.00 (ref) 1.00 (ref)
Analyses adjusted for age and blood loss as restricted cubic splines, 3 df
ns not significant, ref reference
*p < 0.05; **p < 0.01; ***p < 0.001
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80 % of the patients with rectal cancer received neo-
adjuvant (chemo) radiotherapy, and in total 36 % of all
patients received any neo-adjuvant oncological treat-
ment, down staging might have occurred in about a
third of patients.
The risk for recurrence was associated with preoper-
ative anaemia in the log-rank test but the confidence
interval in the multivariate analysis did just include 1
(0.97–2.6) and was thus not significant. However, anae-
mia was significantly associated with the risk for recur-
rence in the model including both anaemia and transfu-
sion. Therefore, this could be described as a trend and
possibly this would have been significant in both
models if the sample size was larger. More advanced
T and N stage was associated with an increased risk
for recurrence in the multivariate model. The association
between anaemia and risk for recurrence has previously
been shown in a recent study on stage II CRCs where
anaemia was shown to be associated with a reduction in
recurrence-free survival in T3N0M0 colon cancer pa-
tients only, but not in patients with T4N0M0 colon can-
cers [13]. In that study, adjustment was made for tu-
mour but not for patient characteristics.
Blood transfusion, often defined in studies as given
within 30 days before and after surgery, has repeatedly
been found to be associated with an increased risk for
recurrence [10]. Although there is little specific data on
the mechanisms behind such an association, it has typ-
ically been attributed to the immunological side effects
of blood transfusion [23]. The recurrence risk described
previously was independent of tumour stage or when
the transfusion was administered [10]. In the present
study, no association was found between transfusion
and risk for recurrence. The effect of transfusions ad-
ministered within a day or 30 days before or after sur-
gery showed practically identical results.
Anaemia prior to surgery, gender, ASA and pN-stage
class were significantly associated with increased overall
mortality regardless of tumour stage. The present study
only included CRC patients stages I–III with curative
abdominal resection, where all early postoperative
deaths were excluded, making the cohort homogenous.
Anaemia was associated with increased overall mortality
in both the analysis for anaemia alone and in the com-
bined analysis for anaemia and transfusion. The multi-
variate analyses revealed no association between trans-
fusion and increased overall mortality although the log-
rank test of the univariate Kaplan-Meyer model was
significant.
Little is known about preoperative anaemia and the
risk for death in patients operated for CRC [11–13].
Previous studies have shown an association between
mild anaemia preoperatively and reduced overall surviv-
al 3–8 years after surgery in patients with CRC stages
I–IV [12]. That study focused on the association be-
tween preoperative symptoms and survival [12]. Mild
anaemia was associated with a more advanced stage
but stage was not entered into the multivariate analyses
Fig. 2 Proportion of patients,
operated for CRC stages I–III,
without recurrence divided in
patients receiving blood
transfusion within a day before or
after surgery or not. p value
represents log-rank test
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[12]. The negative effect of preoperative anaemia on
survival was also confirmed in another study including
patients after both curative and palliative surgery [11].
Hazard ratios were virtually unaffected when
analysing anaemia and transfusion as independent vari-
ables in the various multivariate models compared to
HRs in the combined model although the association
between anaemia and recurrence did not reach statistical
significance in the model including only anaemia.
Preoperative anaemia was, in both models, a significant
risk factor for overall mortality. We were unable to
show that transfusion has an impact on these outcomes
in the multivariate models. It can be argued not to in-
clude both anaemia and blood transfusion in the same
model since they are dependent of each other but, we
believe, that showing both the separate models and the
combined model increases the robustness of the results.
The results of the present study stand in stark contrast
to the conclusions of two meta-analyses where periop-
erative blood transfusion was considered to be consis-
tently associated with risk for recurrence [10, 24]. One
possible explanation could be that the Karolinska
University hospital began using leucocyte-depleted
blood components in 1997, so that all patients included
Table 4 Multivariate Cox
regression analysis for overall
mortality of 496 patients
undergoing curative abdominal

















Yes 95/1058.5 2.1 (1.4–3.2)** 2.3 (1.5–3.6)***
No 36/1129.4 1.00 (ref) 1.00 (ref)
Transfusion
Red blood cell 67/848 1.04 (0.7–1.6) ns 0.8 (0.5–1.2) ns
No transfusion 64/1339.9 1.00 (ref) 1.00 (ref)
Sex
Female 53/1066.9 0.6 (0.4–0.9)* 0.6 (0.4–0.9)** 0.6 (0.4–0.9)*
Male 78/1121 1.00 (ref) 1.00 (ref)
ASA grade
1 11/382.3 1.00 (ref) 1.00 (ref) 1.00 (ref)
2 49/1147 1.1 (0.5–2.3) ns 1.2 (0.6–2.4) ns 1.1 (0.5–2.4) ns
3 57/576.8 1.9 (0.9–4.1) ns 2.2 (1–4.7)* 2 (0.96–4.4) ns
4 14/81.7 3.8 (1.6–9.2)** 4 (1.6–10)** 4.3 (1.7–10.6)**
pT
1 5/270.2 1.00 (ref) 1.00 (ref) 1.00 (ref)
2 23/411.5 2.3 (0.8–6) ns 2.3 (0.9–6.2) ns 2.2 (0.8–6) ns
3 68/1163.5 1.4 (0.6–3.6) ns 1.8 (0.7–4.5) ns 1.4 (0.6–3.7) ns
4 35/342.7 1.8 (0.7–5) ns 2.5 (0.9–6.7) ns 1.9 (0.7–5.1) ns
pN
0 86/1565.1 1.00 (ref) 1.00 (ref) 1.00 (ref)
1 20/463.8 0.8 (0.5–1.4) ns 0.9 (0.5–1.4) ns 0.8 (0.5–1.4) ns
2 25/159 3.6 (2.2–5.8)*** 3.8 (2.3–6.1) *** 3.6 (2.2–5.9)***
Type of surgery
Colon resection 84/1187.7 1.00 (ref) 1.00 (ref) 1.00 (ref)
Low anterior
resection + Hartmann
24/642 0.6 (0.3–1.2) ns 0.5 (0.2–1.1) ns 0.5 (0.3–1.1) ns
Abdomino-perineal
resection
23/358.2 0.8 (0.3–1.8) ns 0.7 (0.3–1.8) ns 0.7 (0.3–1.7) ns
Neo-adjuvant treatment
Yes 40/820.8 1.4 (0.7–3) ns 1.4 (0.7–3) ns 1.5 (0.7–3.1) ns
No 91/1367.1 1.00 (ref) 1.00 (ref) 1.00 (ref)
Analyses adjusted for age and blood loss as restricted cubic splines, 3 df
*p < 0.05; **p < 0.01; ***p < 0.001
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in this study received these presumably less immune-
modulatory blood components [23]. In addition, one
must also consider the possibility of our study being
under powered. While this may be indicated by the
comparatively low statistical precision it must be kept
in mind that the upper confidence interval for the
Fig. 3 Proportion of patients,
operated for CRC stages I–III,
alive divided in patients with
preoperative anaemia and no
anaemia. p value represents log-
rank test
Fig. 4 Proportion of patients,
operated for CRC stages I–III,
alive divided in patients receiving
blood transfusion within a day
before or after surgery or not. p
value represents log-rank test
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estimate of the effect of blood transfusion on the risk
for recurrence was 1.3. This would imply a lesser effect
than that derived in the previous meta-analyses [10, 23].
Conclusion
Preoperative anaemia, present in almost half of our
CRC patients, was strongly associated with increased
risk for overall mortality but not for recurrence. Blood
transfusion was not associated with increased risk for
recurrence or mortality.
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